Navigation Links
Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Date:10/24/2007

ble, locally advanced or metastatic NSCLC who have not previously received chemotherapy for this condition.

Prostate Cancer

Taxotere(R) in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.

Gastric Cancer

Taxotere(R) in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.

Head and Neck Cancer

Taxotere(R) in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

About TAXOTERE(R)

Important safety information

WARNING:

Taxotere(R) treatment can cause serious, physically limiting, and potentially life-threatening side effects, such as infection, low blood-cell counts, allergic reaction and retention of excess fluid (edema).

Taxotere(R) should not be given to patients with low white-blood-cell counts, abnormal liver function, or a history of allergic reactions to Taxotere(R) or any of the ingredients in Taxotere(R).

Before each Taxotere(R) treatment, all patients treated with Taxotere(R) must receive another medicine called dexamethasone. This drug can help reduce the risk of fluid retention (edema) and allergic reactions.

Taxotere(R) should be administered only under the supervision of a qualified physician experienced in the use of anticancer treatments. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.

Treatment-related acute myeloid leukemia (AML) has occurred in patients given anthracyclines and/or cyclophosphamide, including use with Taxotere(R) in adjuvant therapy for breast cancer. The most common sever
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
10. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
11. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... -- The North American dental lasers market was ... reach $90.7 million by 2019, at a CAGR of 9.2% ... of North America Dental Lasers Market for an analysis of ... and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ...   Dental lasers are specifically used in oral ...
(Date:5/22/2015)... and KING OF PRUSSIA, Pa. , ... (NHF) has awarded CSL Behring its 2015 Corporate ... commitment to advancing science and improving the care of the ... Perreault , CEO and Managing Director, CSL Limited, during the ... on May 21. "The National Hemophilia ...
(Date:5/22/2015)... , May 22, 2015 ... Assay Market by Product (Consumables, Instruments, Services), by Test ... (ELISA, Chromatography, Flow Cytometry), by End Users - Global ... Assays Market is expected to reach $736.85 Million by ... CAGR of 10.25%. Browse 71 market ...
Breaking Medicine Technology:North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4
... 2010 Ambit Biosciences (Ambit), today announced ... two products AC430, a selective Janus Kinase 2 (JAK2) ... Phase I trial for AC430 is a two part, ... healthy volunteers.  AC430 will be administered orally once-daily and ...
... Mass., Dec. 20, 2010 The Center for Business Intelligence ... in Massachusetts in 2009. The honor was awarded recently to ... and The Commonwealth Institute at the Boston Park Plaza Hotel. ... Massachusetts for 2009 collectively represent over $47.5B in annual revenue ...
Cached Medicine Technology:Ambit Biosciences Initiates Two Phase I Clinical Trials 2The Center for Business Intelligence (CBI) Receives Top 100 Women-Led Businesses Award 2
(Date:5/26/2015)... Colorado (PRWEB) May 26, 2015 DENVER ... industry expands and evolves, it is also experiencing many ... And like their mainstream counterparts, one major issue that ... to recycle the tons of paper and plastic that ... , “Where others see waste we see the opportunity ...
(Date:5/26/2015)... Javon Bea President and CEO Mercy Health ... quality improvement and organizational development expertise in Mercy ... and direction for the financial, budget, marketing and clinical ... and Mercy Durable Medical Equipment. , Denise has 31 ... last 20 in home care administration. In addition to ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 The professionals ... are at it again, helping local rescue pets with ... Local dentists, Kirk Kimmerling DDS, Suzanna Aguilera DMD ... Julian Peckich DVM donating 100% of proceeds from the ... fill the parking lot to help save unwanted, local ...
(Date:5/25/2015)... Author Vincent N. Cefalu, Sr., MD. has always believed that ... of them aren’t aware of many products that are detrimental ... realize the dangers of physical inactivity and the many dangerous ... exist. There is also the fact that smokers ... In “ A Doctor’s Prescription for Longevity and Survival ” ...
(Date:5/25/2015)... New York (PRWEB) May 25, 2015 ... of patented products, launches The Preventer, a home patent ... the dangers of fire. , "House fires cost the ... Scott J. Cooper, CEO and Creative Director of ... fire deaths result from homes that have no alarmed ...
Breaking Medicine News(10 mins):Health News:Colorado Cannabis Business Expands its Recycling Initiative, to Encourage Marijuana Retailers to Keep Their Businesses Green 2Health News:Colorado Cannabis Business Expands its Recycling Initiative, to Encourage Marijuana Retailers to Keep Their Businesses Green 3Health News:"Rescue Animal Cookout" Announced at Verde Pointe Professional Park on June 25, 2015 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 3Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 2Health News:Home Maintenance Causes House Fires? World Patent Marketing Introduces the Best Home Patent to Prevent Fire Accidents 3
... WATERTOWN, Mass., July 7 , , , WHAT: ... trial in Alzheimer,s disease patients with its, ... WHEN: Wednesday, July 15, 2009., WHERE: ... on Alzheimer,s Disease (ICAD) in Vienna, Austria., WHO: ...
... NEW BRUNSWICK, N.J., July 7 Johnson & Johnson will ... (Eastern Time) on Tuesday, July 14, 2009, to review second-quarter ... Officer, and Louise Mehrotra, Vice President, Investor Relations, will host ... may access the broadcast by visiting the Company,s website at ...
... , WILTON, Conn., July 7 Startech Environmental Corp. (OTC BB: ... its shareholders not to take any action with respect to the ... LRL Holdings LLC to purchase all of the outstanding shares of ... Startech board of directors today said that it will carefully review ...
... (Nasdaq: HMSY ) today announced that it had ... of the Governor, Division of Medicaid (DOM) to provide various ... government insurers, commercial and Medicare recoveries, Medicare Buy-In services, and ... also includes pharmacy data matches to be transmitted to pharmacies ...
... Holdings Group, Inc. (Other OTC: CTYX.PK) today announced that the Company ... June 30, 2009, on Pink Sheets. , , The ... decreasing its net loss by 50% for the second quarter of ... had a net loss of $79,679 for the second quarter of ...
... "This is a fully equipped bio-safety level 2 laboratory dedicated ... Medical Affairs for Medizone. "This new laboratory is located ... in the country and will provide a primary research and ... is now a clear path to commercialization with its lead ...
Cached Medicine News:Health News:EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference on Alzheimer's Disease 2Health News:Startech Environmental Advises Shareholders to Take No Action in Response to Friendly LRL Tender Offer 2Health News:Startech Environmental Advises Shareholders to Take No Action in Response to Friendly LRL Tender Offer 3Health News:Connectyx Technologies Holdings Group, Inc. Increases Revenues by 45% and Reduces Expenses by 20% for the Second Quarter of 2009 Versus Second Quarter 2008 2Health News:Connectyx Technologies Holdings Group, Inc. Increases Revenues by 45% and Reduces Expenses by 20% for the Second Quarter of 2009 Versus Second Quarter 2008 3Health News:Medizone International, Inc. (MZEI.PK) Announces it has Established its Own BSL2A Certified Laboratory Located in Innovation Park, Queen's University at Kingston, Ontario, Canada. 2
... The HemoPoint H2 Hemoglobin Measurement ... determination of hemoglobin in arterial, venous, ... infants, and children in a professional ... number 3010-100 is indicated for use ...
... A dip-and-read urinalysis product available for ... systems. Clinitek® Microalbumin Strips provide albumin, ... one minute. The Clinitek® Microalbumin product ... in patients with diabetes or hypertension ...
... Thin Film technology is here! LTF™ (Layered ... rapid point-of-care test platform that is easy ... and thin as a credit card. What ... number one reason women visit their physician. ...
... The InstaCheck® multi-drug test ... simply and easily. Negative results ... few as 3 minutes; positive ... A simple, one-time urine sample ...
Medicine Products: